Skip to content
Inciteful Med

The Genetics of BWS: Switches and Subtypes

Last updated:

Beckwith-Wiedemann Syndrome (BWS) has four main genetic subtypes: IC2-LoM, pUPD11, IC1-GoM, and CDKN1C. Identifying your child's exact subtype is essential because it determines their specific risk for childhood cancers and dictates their customized tumor screening schedule.

Key Takeaways

  • • BWS is caused by genomic imprinting errors on the 11p15.5 region of chromosome 11.
  • • There are four main molecular subtypes of BWS: IC2-LoM, pUPD11, IC1-GoM, and CDKN1C mutations.
  • • A child's specific subtype dictates their unique risk for developing childhood tumors like Wilms tumor, hepatoblastoma, and neuroblastoma.
  • • IC1-GoM carries the highest risk for Wilms tumor, while IC2-LoM is the most common subtype and carries the lowest overall tumor risk.
  • • Doctors use your child's exact genetic subtype to create a customized surveillance schedule to proactively monitor for specific cancers.

Understanding the genetics of Beckwith-Wiedemann Syndrome (BWS) is the key to managing your child’s health. While the terminology can be complex, it helps to think of it like a set of electrical circuits and switches that control growth.

The 11p15.5 Region and Imprinting

All of the “blueprints” for BWS are located in a specific area of chromosome 11 called the 11p15.5 region [1]. Inside this region, genes are controlled by a process called genomic imprinting [2].

In a typical child, certain genes have “on/off” switches based on which parent they came from [2][3]. For example, a growth-promoting gene might be “on” from the father but “off” from the mother. In BWS, these switches are set incorrectly—too many growth genes are “on” or too many growth-restricting genes are “off”—leading to the physical features of the syndrome [4][5].

The Four Main Molecular Subtypes

Your child’s “subtype” is determined by which “switch” is broken. This is the most important information for their medical team because it dictates their specific cancer risk and screening schedule [6][7].

Subtype Summary Table

Subtype Frequency Physical Features Tumor Risk Level Primary Tumor Risks Routine AFP Screening?
IC2-LoM ~50% Macroglossia, Abdominal wall defects Lowest (2.5%) Hepatoblastoma (rare) Generally not recommended
pUPD11 ~20% Lateralized overgrowth, Severe hypoglycemia High (~14-16%) Wilms tumor, Hepatoblastoma Yes
IC1-GoM ~5-10% Extreme macrosomia, Enlarged organs Highest (~28%) Wilms tumor Generally not recommended
CDKN1C ~5% Omphalocele Moderate (~7-9%) Neuroblastoma No (Requires urine screening)

1. IC2-LoM (Loss of Methylation)

This is the most common cause of BWS, affecting about 50% of cases [5].

  • Physical Features: Often associated with macroglossia (large tongue) and abdominal wall defects, but these children are less likely to have macrosomia (large body size) [8][9].
  • Cancer Risk: Generally considered the lowest risk group for tumors (about 2.5%) [10][11].

2. pUPD11 (Paternal Uniparental Disomy)

This happens when a child inherits two copies of this region from their father and none from their mother [12].

  • Physical Features: Very likely to have lateralized overgrowth (one side of the body larger than the other) and severe low blood sugar at birth [13][14].
  • Cancer Risk: Carries a higher risk for several tumors, including Wilms tumor (kidney) and hepatoblastoma (liver) [10][13].

3. IC1-GoM (Gain of Methylation)

In this subtype, a growth-promoting switch is stuck in the “on” position [5].

  • Physical Features: Often results in extreme macrosomia (being very large at birth) and enlarged internal organs like the liver or kidneys [8][9].
  • Cancer Risk: This group has the highest risk for Wilms tumor (up to 22.8% to 28%) [10][15].

4. CDKN1C Mutations

This is a change in a specific gene that normally acts as a “brake” on growth [16].

  • Physical Features: Often associated with an omphalocele (abdominal wall defect) but less likely to have overgrowth [8].
  • Cancer Risk: These children have a unique risk for neuroblastoma (a type of nerve tissue tumor) but a very low risk for kidney or liver tumors [10][17].

Why Subtypes Matter for Surveillance

Because the risks vary so much, your doctor will tailor your child’s surveillance (screening) protocol [7][18]. For example, a child with IC1-GoM will need very frequent kidney ultrasounds, while a child with pUPD11 will also need regular blood tests (AFP) to watch for liver tumors [10][19]. Knowing your child’s subtype allows the medical team to focus on the most likely risks, providing the best protection while avoiding unnecessary tests where the risk is low [6].

Frequently Asked Questions

What are the four main genetic subtypes of Beckwith-Wiedemann Syndrome?
The four main molecular subtypes of BWS are IC2-LoM, pUPD11, IC1-GoM, and CDKN1C mutations. Each subtype involves a different genetic change on chromosome 11 and causes its own distinct physical features and tumor risk profiles.
Why is it important to know my child's specific BWS subtype?
Knowing your child's specific BWS subtype is crucial because it determines their exact risk for developing certain childhood cancers. This allows your medical team to create a customized tumor screening schedule that focuses on their highest risks while avoiding unnecessary tests.
Which BWS subtype has the highest risk for developing tumors?
Children with the IC1-GoM subtype have the highest overall risk for tumors, particularly Wilms tumor, with a risk level up to 28 percent. In contrast, the IC2-LoM subtype is the most common but carries the lowest tumor risk at around 2.5 percent.
Does my child's BWS subtype explain their low blood sugar at birth?
Yes, certain genetic subtypes are more closely linked to severe hypoglycemia at birth. Specifically, children with the pUPD11 subtype are very likely to experience severe low blood sugar alongside lateralized overgrowth.

Questions for Your Doctor

  • • Which of the four main molecular subtypes (IC1-GoM, IC2-LoM, pUPD11, or CDKN1C) does my child have?
  • • Based on my child's specific subtype, what is their exact risk for Wilms tumor versus hepatoblastoma?
  • • Should we be screening for neuroblastoma, or is that only for children with the CDKN1C subtype?
  • • How does my child's subtype influence the frequency of their ultrasound and AFP blood tests?
  • • Does my child's genetic subtype explain why they did (or did not) have severe low blood sugar after birth?

Questions for You

  • • Has the doctor shared the specific genetic test results (the molecular subtype) with me in writing?
  • • Does my child have lateralized overgrowth (one side larger than the other), which might point toward a specific subtype like pUPD11?
  • • Am I comfortable with the current screening schedule, or do I need more information on why we are testing for certain tumors and not others?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Investigation of (epi)genotype causes and follow-up manifestations in the patients with classical and atypical phenotype of Beckwith-Wiedemann spectrum.

    Tüysüz B, Güneş N, Geyik F, et al.

    American journal of medical genetics. Part A 2021; (185(6)):1721-1731 doi:10.1002/ajmg.a.62158.

    PMID: 33704912
  2. 2

    Concurrent Hepatoblastoma and Wilms Tumor Leading to Diagnosis of Beckwith-Wiedemann Syndrome.

    Wolfe DM, Webster Carrion A, Masukhani MM, et al.

    Journal of pediatric hematology/oncology 2023; (45(4)):e525-e529 doi:10.1097/MPH.0000000000002593.

    PMID: 36730589
  3. 3

    (Epi)genotype-phenotype correlations in Beckwith-Wiedemann syndrome: a paradigm for genomic medicine.

    Mussa A, Russo S, Larizza L, et al.

    Clinical genetics 2016; (89(4)):403-415 doi:10.1111/cge.12635.

    PMID: 26138266
  4. 4

    Beckwith-Wiedemann syndrome: clinical and etiopathogenic aspects of a model genomic imprinting entity.

    Cammarata-Scalisi F, Avendaño A, Stock F, et al.

    Archivos argentinos de pediatria 2018; (116(5)):368-373 doi:10.5546/aap.2018.eng.368.

    PMID: 30204990
  5. 5

    Disruption of KCNQ1 prevents methylation of the ICR2 and supports the hypothesis that its transcription is necessary for imprint establishment.

    Beygo J, Bürger J, Strom TM, et al.

    European journal of human genetics : EJHG 2019; (27(6)):903-908 doi:10.1038/s41431-019-0365-x.

    PMID: 30778172
  6. 6

    Molecular Basis of Beckwith-Wiedemann Syndrome Spectrum with Associated Tumors and Consequences for Clinical Practice.

    Eggermann T, Maher ER, Kratz CP, Prawitt D

    Cancers 2022; (14(13)) doi:10.3390/cancers14133083.

    PMID: 35804856
  7. 7

    [Beckwith-Wiedemann Syndrome (BWS) Current Status of Diagnosis and Clinical Management: Summary of the First International Consensus Statement].

    Elbracht M, Prawitt D, Nemetschek R, et al.

    Klinische Padiatrie 2018; (230(3)):151-159 doi:10.1055/a-0591-9479.

    PMID: 29660755
  8. 8

    Fetal growth patterns in Beckwith-Wiedemann syndrome.

    Mussa A, Russo S, de Crescenzo A, et al.

    Clinical genetics 2016; (90(1)):21-7 doi:10.1111/cge.12759.

    PMID: 26857110
  9. 9

    (Epi)genotype-phenotype correlations of Beckwith-Wiedemann syndrome in China.

    Lan D, Zhang S, Li J, et al.

    Italian journal of pediatrics 2025; (51(1)):276 doi:10.1186/s13052-025-02122-4.

    PMID: 41024278
  10. 10

    Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol.

    Mussa A, Molinatto C, Baldassarre G, et al.

    The Journal of pediatrics 2016; (176()):142-149.e1.

    PMID: 27372391
  11. 11

    Beckwith-Wiedemann syndrome: Clinical, histopathological and molecular study of two Tunisian patients and review of literature.

    Sassi H, Elaribi Y, Jilani H, et al.

    Molecular genetics & genomic medicine 2021; (9(10)):e1796 doi:10.1002/mgg3.1796.

    PMID: 34510813
  12. 12

    Imprinted disorders and growth.

    Giabicani É, Brioude F, Le Bouc Y, Netchine I

    Annales d'endocrinologie 2017; (78(2)):112-113 doi:10.1016/j.ando.2017.04.010.

    PMID: 28478949
  13. 13

    Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study.

    Cöktü S, Spix C, Kaiser M, et al.

    British journal of cancer 2020; (123(4)):619-623 doi:10.1038/s41416-020-0911-x.

    PMID: 32451468
  14. 14

    Determinants of Hyperinsulinism Severity in Children with Beckwith-Wiedemann Syndrome.

    George AM, Viswanathan A, Sussman JH, et al.

    The Journal of clinical endocrinology and metabolism 2026; doi:10.1210/clinem/dgag053.

    PMID: 41655234
  15. 15

    Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups.

    Maas SM, Vansenne F, Kadouch DJ, et al.

    American journal of medical genetics. Part A 2016; (170(9)):2248-60 doi:10.1002/ajmg.a.37801.

    PMID: 27419809
  16. 16

    CDKN1C -Related Beckwith-Wiedemann Syndrome: First Patient from India.

    Arora V, Takkar A, Dubey S, et al.

    Journal of pediatric genetics 2024; (13(4)):330-334 doi:10.1055/s-0043-1764126.

    PMID: 39502854
  17. 17

    Expanded phenotype and cancer risk in patients with Beckwith-Wiedemann spectrum caused by CDKN1C variants.

    George AM, Viswanathan A, Best LG, et al.

    American journal of medical genetics. Part A 2024; (194(10)):e63777 doi:10.1002/ajmg.a.63777.

    PMID: 38822599
  18. 18

    Recommendations of the Scientific Committee of the Italian Beckwith-Wiedemann Syndrome Association on the diagnosis, management and follow-up of the syndrome.

    Mussa A, Di Candia S, Russo S, et al.

    European journal of medical genetics 2016; (59(1)):52-64.

    PMID: 26592461
  19. 19

    Adrenal Cortical Neoplasm with Uncertain Malignant Potential Arising in the Heterotopic Adrenal Cortex in the Liver of a Patient with Beckwith-Wiedemann Syndrome.

    Kim EN, Song DE, Yoon HM, et al.

    Journal of pathology and translational medicine 2019; (53(2)):129-135 doi:10.4132/jptm.2018.11.13.

    PMID: 30472817

This page provides educational information about Beckwith-Wiedemann Syndrome genetics and tumor risks. Always consult your pediatric geneticist or oncologist to discuss your child's specific subtype and clinical screening plan.

Stay up to date

Get notified when new research about Beckwith-Wiedemann syndrome is published.

No spam. Unsubscribe anytime.